Polycomb group protein enhancer of zeste 2 is an oncogene that promotes the neoplastic transformation of a benign prostatic epithelial cell line

Molecular Cancer Research

Volumn 7, Issue 9, 2009, Pages 1456-1465

  Karanikolas, Breanne D W ^a   Figueiredo, Marxa L ^b   Wu, Lily ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b LOUISIANA STATE UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

POLYCOMB GROUP PROTEIN ENHANCER OF ZESTE 2; PROTEIN KINASE B; RAS PROTEIN; REGULATOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GRAFT; CARCINOGENESIS; CELL FUNCTION; CELL TRANSFORMATION; COLONY FORMATION; CONTROLLED STUDY; EPITHELIUM CELL; GENE ACTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; ONCOGENE; PHENOTYPE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY;

ANIMALS; CELL LINE; CELL TRANSFORMATION, NEOPLASTIC; DNA-BINDING PROTEINS; EPITHELIAL CELLS; GREEN FLUORESCENT PROTEINS; IMMUNOHISTOCHEMISTRY; LENTIVIRUS; MALE; MICE; MICE, SCID; NEOPLASM INVASIVENESS; NEOPLASM TRANSPLANTATION; PROSTATIC HYPERPLASIA; PROTEIN METHYLTRANSFERASES; PROTO-ONCOGENE PROTEINS C-AKT; TRANSCRIPTION FACTORS; WHOLE BODY IMAGING;

EID: 70349515386     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-09-0121     Document Type: Article

References (67)

1. Brock HW, van Lohuizen M. The polycomb group - no longer an exclusive club? Curr Opin Genet Dev 2001;11:175-181
2. Orlando V. Polycomb, epigenomes, and control of cell identity. Cell 2003;112:599-606. (Pubitemid 36331773)
3. Cao R, Zhang Y. SUZ12 is required for both the histone methyltransferase activity and the silencing function of the EED-EZH2 complex. Mol Cell 2004;15:57-67. (Pubitemid 38850219)
4. Sewalt RG, van der Vlag J, Gunster MJ, et al. Characterization of interactions between the mammalian polycomb-group proteins Enx1/EZH2 and EED suggests the existence of different mammalian polycomb-group protein complexes. Mol Cell Biol 1998;18:3586-3595
5. Bunker CA, Kingston RE. Transcriptional repression by Drosophila and mammalian polycomb group proteins in transfected mammalian cells. Mol Cell Biol 1994;14:1721-1732
6. Cao R, Wang L, Wang H, et al. Role of histone H3 lysine 27 methylation in polycomb-group silencing. Science 2002;298:1039-1043 (Pubitemid 35247314)
7. Kirmizis A, Bartley SM, Kuzmichev A, et al. Silencing of human polycomb target genes is associated with methylation of histone H3 Lys 27. Genes Dev 2004;18:1592-1605 (Pubitemid 38868910)
8. Cao R, Zhang Y. The functions of E(Z)/EZH2-mediated methylation of lysine 27 in histone H3. Curr Opin Genet Dev 2004;14:155-164 (Pubitemid 38520143)
9. Jenuwein T, Allis CD. Translating the histone code. Science 2001;293:1074-1080
10. Muller J, Hart CM, Francis NJ, et al. Histone methyltransferase activity of a Drosophila polycomb group repressor complex. Cell 2002;111:197-208. (Pubitemid 35292440)
11. Visser HP, Gunster MJ, Kluin-Nelemans HC, et al. The polycomb group protein EZH2 is upregulated in proliferating, cultured human mantle cell lymphoma. Br J Haematol 2001;112:950-958
12. Varambally S, Dhanasekaran SM, Zhou M, et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002;419:624-629
13. Collett K, Eide GE, Arnes J, et al. Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer. Clin Cancer Res 2006;12:1168-1174 (Pubitemid 43342505)
14. Raaphorst FM, Meijer CJ, Fieret E, et al. Poorly differentiated breast carcinoma is associated with increased expression of the human polycomb group EZH2 gene. Neoplasia 2003;5:481-488 (Pubitemid 38045085)
15. Bachmann IM, Halvorsen OJ, Collett K, et al. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol 2006;24:268-273 (Pubitemid 46622055)
16. McHugh JB, Fullen DR, Ma L, Kleer CG, Su LD. Expression of polycomb group protein EZH2 in nevi and melanoma. J Cutan Pathol 2007;34:597-600. (Pubitemid 47063232)
17. Croonquist PA, Van Ness B. The polycomb group protein enhancer of zeste homolog 2 (EZH 2) is an oncogene that influences myeloma cell growth and the mutant ras phenotype. Oncogene 2005;24:6269-6280 (Pubitemid 43080050)
18. Mattioli E, Vogiatzi P, Sun A, et al. Immunohistochemical analysis of pRb2/p130, VEGF, EZH2, p53, p16(INK4A), p27(KIP1), p21(WAF1), Ki-67 expression patterns in gastric cancer. J Cell Physiol 2007;210:183-191
19. Gil J, Bernard D, Peters G. Role of polycomb group proteins in stem cell self-renewal and cancer. DNA Cell Biol 2005;24:117-125 (Pubitemid 40189747)
20. Saramaki OR, Tammela TL, Martikainen PM, Vessella RL, Visakorpi T. The gene for polycomb group protein enhancer of zeste homolog 2 (EZH2) is amplified in late-stage prostate cancer. Genes Chromosomes Cancer 2006;45:639-645 (Pubitemid 43727151)
21. Varambally S, Cao Q, Mani RS, et al. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science 2008;322:1695-1699
22. Laitinen S, Martikainen PM, Tolonen T, et al. EZH2, Ki-67 and MCM7 are prognostic markers in prostatectomy treated patients. Int J Cancer 2008;122:595-602. (Pubitemid 350308951)
23. Rhodes DR, Sanda MG, Otte AP, Chinnaiyan AM, Rubin MA. Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer. J Natl Cancer Inst 2003;95:661-668
24. Yu J, Yu J, Rhodes DR, et al. A polycomb repression signature in metastatic prostate cancer predicts cancer outcome. Cancer Res 2007;67:10657-10663 (Pubitemid 350145890)
25. Bryant RJ, Cross NA, Eaton CL, Hamdy FC, Cunliffe VT. EZH2 promotes proliferation and invasiveness of prostate cancer cells. Prostate 2007;67:547-556 (Pubitemid 46536947)
26. Kleer CG, Cao Q, Varambally S, et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A 2003;100:11606-11611 (Pubitemid 37205983)
27. Wissmann M, Yin N, Muller JM, et al. Cooperative demethylation by JMJD2C and LSD1 promotes androgen receptor-dependent gene expression. Nat Cell Biol 2007;9:347-353
28. Hayward SW, Dahiya R, Cunha GR, et al. Establishment and characterization of an immortalized but non-transformed human prostate epithelial cell line: BPH-1. In Vitro Cell Dev Biol Anim 1995;31:14-24.
29. Mitchell S, Abel P, Ware M, Stamp G, Lalani E. Phenotypic and genotypic characterization of commonly used human prostatic cell lines. BJU Int 2000;85:932-944 (Pubitemid 30242804)
30. Untergasser G, Rumpold H, Hermann M, et al. Proliferative disorders of the aging human prostate: involvement of protein hormones and their receptors. Exp Gerontol 1999;34:275-287 (Pubitemid 29153024)
31. Phillips JL, Hayward SW, Wang Y, et al. The consequences of chromosomal aneuploidy on gene expression profiles in a cell line model for prostate carcinogenesis. Cancer Res 2001;61:8143-8149 (Pubitemid 33091605)
32. Shou J, Soriano R, Hayward SW, et al. Expression profiling of a human cell line model of prostatic cancer reveals a direct involvement of interferon signaling in prostate tumor progression. Proc Natl Acad Sci U S A 2002;99:2830-2835 (Pubitemid 34240546)
33. Cunha GR, Hayward SW, Wang YZ. Role of stroma in carcinogenesis of the prostate. Differentiation 2002;70:473-485
34. Majumder PK, Sellers WR. Akt-regulated pathways in prostate cancer. Oncogene 2005;24:7465-7474
35. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell 2007;129:1261-1274
36. Majumder PK, Yeh JJ, George DJ, et al. Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: the MPAKT model. Proc Natl Acad Sci U S A 2003;100:7841-7846
37. Sansom OJ, Meniel V, Wilkins JA, et al. Loss of Apc allows phenotypic manifestation of the transforming properties of an endogenous K-ras oncogene in vivo. Proc Natl Acad Sci U S A 2006;103:14122-14127 (Pubitemid 44452990)
38. Bos JL. ras oncogenes in human cancer: a review. Cancer Res 1989;49:4682-4689 (Pubitemid 19213607)
39. Malumbres M, Barbacid M. RAS oncogenes: the first 30 years. Nat Rev Cancer 2003;3:459-465
40. Rosen DG, Yang G, Bast RC, Jr., Liu J. Use of ras-transformed human ovarian surface epithelial cells as a model for studying ovarian cancer. Methods Enzymol 2005;407:660-676 (Pubitemid 43815984)
41. Traynor P, McGlynn LM, Mukhergee R, et al. An increase in N-Ras expression is associated with development of hormone refractory prostate cancer in a subset of patients. Dis Markers 2008;24:157-165 (Pubitemid 352038624)
42. Bakin RE, Gioeli D, Sikes RA, Bissonette EA, Weber MJ. Constitutive activation of the Ras/mitogen-activated protein kinase signaling pathway promotes androgen hypersensitivity in LNCaP prostate cancer cells. Cancer Res 2003;63:1981-1989 (Pubitemid 36460867)
43. Weber MJ, Gioeli D. Ras signaling in prostate cancer progression. J Cell Biochem 2004;91:13-25.
44. Chen H, Tu SW, Hsieh JT. Down-regulation of human DAB2IP gene expression mediated by polycomb Ezh2 complexan d histone deacetylase in prostate cancer. J Biol Chem 2005;280:22437-22444 (Pubitemid 40827899)
45. Miyoshi H, Blomer U, Takahashi M, Gage FH, Verma IM. Development of a self-inactivating lentivirus vector. J Virol 1998;72:8150-8157
46. Xin L, Lawson DA, Witte ON. The Sca-1 cell surface marker enriches for a prostate-regenerating cell subpopulation that can initiate prostate tumorigenesis. Proc Natl Acad Sci U S A 2005;102:6942-6947 (Pubitemid 40675421)
47. Pham H, Eibl G, Vincenti R, et al. 15-Hydroxyprostaglandin dehydrogenase suppresses K-RasV12-dependent tumor formation in nu/nu mice. Mol Carcinog 2008;47:466-477 (Pubitemid 351822305)
48. Cha TL, Zhou BP, Xia W, et al. Akt-mediated phosphorylation of EZH2 suppresses methylation of lysine 27 in histone H3. Science 2005;310:306-310 (Pubitemid 41457195)
49. Yu J, Cao Q, Mehra R, et al. Integrative genomics analysis reveals silencing of β-adrenergic signaling by polycomb in prostate cancer. Cancer Cell 2007;12:419-431 (Pubitemid 350046407)
50. Bracken AP, Pasini D, Capra M, et al. EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J 2003;22:5323-5335 (Pubitemid 37279943)
51. Muller H, Bracken AP, Vernell R, et al. E2Fs regulate the expression of genes involved in differentiation, development, proliferation, and apoptosis. Genes Dev 2001;15:267-285 (Pubitemid 32155143)
52. INK4A regulates polycomb-mediated DNA hypermethylation in human mammary epithelial cells. J Biol Chem 2006;281:24790-24802
53. Tang X, Milyavsky M, Shats I, et al. Activated p53 suppresses the histone methyltransferase EZH2 gene. Oncogene 2004;23:5759-5769 (Pubitemid 39093021)
54. Attwooll C, Oddi S, Cartwright P, et al. A novel repressive E2F6 complex containing the polycomb group protein, EPC1, that interacts with EZH2 in a proliferation-specific manner. J Biol Chem 2005;280:1199-1208
55. Tonini T, Bagella L, D'Andrilli G, Claudio PP, Giordano A. Ezh2 reduces the ability of HDAC1-dependent pRb2/p130 transcriptional repression of cyclin A. Oncogene 2004;23:4930-4937 (Pubitemid 38932165)
56. Bryant RJ, Winder SJ, Cross SS, Hamdy FC, Cunliffe VT. The polycomb group protein EZH2 regulates actin polymerization in human prostate cancer cells. Prostate 2008;68:255-263
57. INK4α tumor suppressor gene. Genes Dev 2007;21:49-54.
58. Dull T, Zufferey R, Kelly M, et al. A third-generation lentivirus vector with a conditional packaging system. J Virol 1998;72:8463-8471 (Pubitemid 28471781)
59. Laible G, Wolf A, Dorn R, et al. Mammalian homologues of the polycomb-group gene enhancer of zeste mediate gene silencing in Drosophila heterochromatin and at S. cerevisiae telomeres. EMBO J 1997;16:3219-3232 (Pubitemid 27234960)
60. Burton JB, Priceman SJ, Sung JL, et al. Suppression of prostate cancer nodal and systemic metastasis by blockade of the lymphangiogenic axis. Cancer Res 2008;68:7828-7837
61. Soneoka Y, Cannon PM, Ramsdale EE, et al. A transient three-plasmid expression system for the production of high titer retroviral vectors. Nucleic Acids Res 1995;23:628-633
62. Aschenbrenner L, Lee T, Hasson T. Myo6 facilitates the translocation of endocytic vesicles from cell peripheries. Mol Biol Cell 2003;14:2728-2743 (Pubitemid 36871517)
63. Brakenhielm E, Burton JB, Johnson M, et al. Modulating metastasis by a lymphangiogenic switch in prostate cancer. Int J Cancer 2007;121:2153-2161 (Pubitemid 47585593)
64. Lochter A, Werb Z, Bissell MJ. Transcriptional regulation of stromelysin-1 gene expression is altered during progression of mouse mammary epithelial cells from functionally normal to malignant. Matrix Biol 1999;18:455-467
65. Sorensen AG, Patel S, Harmath C, et al. Comparison of diameter and perimeter methods for tumor volume calculation. J Clin Oncol 2001;19:551-557 (Pubitemid 32112870)
66. Tomayko MM, Reynolds CP. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol 1989;24:148-154
67. Winer J, Jung CK, Shackel I, Williams PM. Development and validation of real-time quantitative reverse transcriptase-polymerase chain reaction for monitoring gene expression in cardiac myocytes in vitro. Anal Biochem 1999;270:41-49 (Pubitemid 29230718)